Evidence map›Paper›PMID 40125810›Full record

ArticleCNS neuroscience & therapeutics2025

A Novel Compound QO-83 Alleviates Acute and Chronic Epileptic Seizures in Rodents by Modulating K

Xiangyu Wang, Yang Zhang, Hui Liu, Jiahao Wang, Boxuan Zhang, Tenghui He, Huiran Zhang, Zhumei Xiong, Xingang Liu, Jincan Li and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xiangyu WangHebei Medical University, Postdoctoral Mobile Station of Basic Medical, Hebei Medical University, Shijiazhuang, China.
Yang ZhangCollege of Pharmacy, Hebei Medical University, Shijiazhuang, China.
Hui LiuDepartment of Neurobiology, Hebei Medical University, Shijiazhuang, China.
Jiahao WangDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, China.
Boxuan ZhangDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, China.
Tenghui HeDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, China.
Huiran ZhangCollege of Pharmacy, Hebei Medical University, Shijiazhuang, China.
Zhumei XiongDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, China.
Xingang LiuCollege of Pharmacy, Hebei Medical University, Shijiazhuang, China.
Jincan LiCollege of Pharmacy, Hebei Medical University, Shijiazhuang, China.
Weidong ZhaoDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, China.
Xiao LiuDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, China.
Wei ZhangDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, China.
Le YangDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, China.
Qian LiDepartment of Pharmacy, Shijiazhuang Fifth Hospital, Shijiazhuang, China.
Hailin ZhangHebei Medical University, Postdoctoral Mobile Station of Basic Medical, Hebei Medical University, Shijiazhuang, China.
Jinlong QiDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, China.
Qingzhong JiaDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, China.

Funding

Foundation Postdoctoral Mobile Station of Basic Medical Sciences, Hebei Medical University 20123120019Hebei Medical University, Science and Technology CYQD2023014Hebei Provincial Department of Human Resources and Social Security B2023003034Key Research and Development Plan Project of Shijiazhuang 241200263AScience and technology research project of colleges and universities in Hebei Province QN2023197Science Research Project of Hebei Education Department CXY2024051the Central Guidance on Local Science and Technology Development Fund of Hebei Province 226Z2602Gthe Key Project from Hebei Provincial Department of science and Technology 21372601Dthe Natural Science Foundation of Hebei province H2022206201
6 · The paper itself

Abstract

aimsK

methodsWe used patch-clamp electrophysiology, electroencephalogram recordings, dynamic simulations, and various epilepsy models to investigate the mechanisms and antiepileptic activity of QO-83.

resultsCompound QO-83 exhibits greater potency at K

conclusionQO-83, as a newly developed Kv7.2 opener, has the advantages of stable properties, strong affinity, and high activity compared with retigabine, and is expected to become a new antiepileptic drug.

Indexed as

AnticonvulsantsEpilepsyKCNQ Potassium ChannelsSeizuresAnimalsCarbamatesChronic DiseaseDisease Models, AnimalDose-Response Relationship, DrugElectroencephalographyHippocampusHumansKCNQ2 Potassium ChannelMaleMicePatch-Clamp TechniquesAnticonvulsantsCarbamatesezogabineKCNQ2 Potassium ChannelKCNQ Potassium ChannelsPhenylenediaminesepilepsyKV7 channelneurological disorderpyramidal neuronsQO‐83

Identifiers

PMID40125810
PMCPMC11931445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.